Abstract
Quetiapine (Seroquel®) is a new atypical antipsychatic agent which has been already released in the UK and US 1997 and which is currently also available in Germany for the treatment of schizophrenio spectrum disorders. Quetiapine is an antipsychatic from a novel pharmacologic group - a dibenzothiazepine derivative. In clinical acute phase studies its efficacy for treating positive symptoms was comparable to typical neuraleptics, mainly haloperidol. A better efficacy in the treatment of negative symptoms could not yet be shown, also in patients with predominant negative symptoms. Especially regarding extrapyramidal sideeffects quetiapine is comparable to the reference substance clozapine with no dose-dependent increase when the therapeutical dosis range is applied. The frequency and extent of body weight gain is like that seen under risperidone, additionally no rise of prolactin levels has been observed according to current data. A problem of quetiapine is the initial severe sedation.
| Translated title of the contribution | Quetiapine: a new atypical antipsychotic in the treatment of schizophrenic patients |
|---|---|
| Original language | German |
| Pages (from-to) | 338-351 |
| Number of pages | 14 |
| Journal | Nervenheilkunde |
| Volume | 20 |
| Issue number | 6 |
| Publication status | Published - 2001 |
| Externally published | Yes |
Keywords
- Atypical antipsychotic
- Quetiapine
- Review
- Schizaphrenia